Small Business Innovation Research · Small Business Technology Transfer
Paramita Therapeutics, Inc.: SBIR & STTR awards
2 awards worth $609.0K to 1 companies since 2021 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
Paramita Therapeutics, Inc.'s federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2025 | 1 | 0 | $353.0K |
| 2021 | 1 | 0 | $256.0K |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
By agency
- Department of Health and Human Services 1 awards · $353.0K
- National Science Foundation 1 awards · $256.0K
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| Novel multivalent PSMA-targeted taxane-conjugates for bone metastases in prostate cancer · topic 102 | Paramita Therapeutics, Inc. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $353.0K | 2025-09-24 |
| SBIR Phase I: Novel COVID-19 Dual-function Therapeutic/Vaccine Product · topic PT | Paramita Therapeutics, Inc. · California | National Science Foundation | SBIR Phase I | $256.0K | 2021-05-01 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.